Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EC receives 26 vigilance reports in two months:

This article was originally published in Clinica

Executive Summary

A total of 26 medical device vigilance reports were sent by the regulatory authorities in the European Economic Area and by the Swiss medical device authority to the European Commission between January 29 and March 26 2003. According to the Commission, the majority of these reports came from Germany, a total of 11 in all, while the UK was the next most active reporter, having sent six reports. The remaining reports came from Belgium (1), France (3), the Netherlands (1), Norway (1), and Switzerland (1). Vigilance reports are those adverse incident reports that have been received by the competent authorities from medical device manufacturers and users and which are deemed serious enough to need to be communicated to all authorities in Europe so that joint action can be taken to tackle the health threat represented by the device.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel